Previous 10 | Next 10 |
Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...
Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
BUFFALO, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly en...
Shares of Athenex (NASDAQ: ATNX) rose nearly 44% today after the company announced that it will present at the upcoming San Antonio Breast Cancer Symposium on December 13. That's not really news, as companies present at scientific meetings and conferences all the time. But astute inve...
Gainers: SAExploration (NASDAQ: SAEX ) +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...
Abstract selected for the SABCS press program Oral presentation of Oral Paclitaxel and encequidar Phase III results on December 13 Company to host a Key Opinion Leader webcast event for the investment community BUFFALO, N.Y., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NA...
Athenex, Inc. (ATNX) Q3 2019 Earnings Conference Call November 7, 2019 08:00 ET Company Participants Tim McCarthy - Investor Relations Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Rudolf Kwan - Chief Medical Officer Randoll Sze - Chief Financial...
Image source: The Motley Fool. Athenex, Inc. (NASDAQ: ATNX) Q3 2019 Earnings Call Nov 8, 2019 , 3:00 a.m. ET Operator Continue reading
Athenex (NASDAQ: ATNX ): Q3 GAAP EPS of -$0.45 in-line. More news on: Athenex, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2 million of product sales in Q3 2019, a 45% year-over-year increase Raising full year 2019 guidance to 35% to...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...